VIC aims to advance research initiatives efficiently from discovery through the preclinical stage to early clinical testing to enable successful product development by an industry or a non-profit partner.
There are now 9 novel medical products under development at VIC targeting specific cancers, infectious and immune mediated diseases including mesothelioma, Q fever and type 1 diabetes. These products are broadly applicable and include devices, cell therapies and the repurposing of immunomodulatory small molecules and the invention of biologics.
The model encompasses:
Innovative translational bench to bedside science team
Training and career development for next generation of translational scientists
Distributed development with best in class collaborators
Assiduous project management and product development
Position projects for effective translational hand-off, including foundation for regulatory review